Focused On-demand Library for E3 ubiquitin-protein ligase MARCHF7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H992

UPID:

MARH7_HUMAN

Alternative names:

Axotrophin; Membrane-associated RING finger protein 7; Membrane-associated RING-CH protein VII; RING finger protein 177; RING-type E3 ubiquitin transferase MARCHF7

Alternative UPACC:

Q9H992; A8K9X1; B7Z7P5; D3DPB0; Q53GQ1; Q9BTR9

Background:

E3 ubiquitin-protein ligase MARCHF7, known by alternative names such as Axotrophin and Membrane-associated RING finger protein 7, plays a crucial role in protein ubiquitination, impacting cellular processes like T-cell proliferation and lysosome homeostasis. Its activity involves enhancing the E2 enzyme HIP2 for targeted substrate ubiquitination.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase MARCHF7 could open doors to potential therapeutic strategies, particularly in modulating immune responses and maintaining cellular health.